Clinical efficacy trial of PRX 106 (oral anti-TNF) for the treatment of inflammatory bowel disease.
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2015
At a glance
- Drugs Etanercept (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Protalix Biotherapeutics
- 09 Nov 2015 According to Protalix Bio Therapeutics media release, the company anticipates commencing this trial by the first quarter of 2016,
- 27 Jan 2015 New trial record
- 05 Jan 2015 Results are expected in early 2016.